(Q41060497)

26 September 2017

1 reference

title

Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia (English)

1 reference

26 September 2017

0 references

1 reference

C M Spencer

1

1 reference

PubMed ID

8736620

26 September 2017

L B Barradell

series ordinal

2

1 reference

26 September 2017

1 June 1996

1 reference

26 September 2017

1 reference

26 September 2017

51

1 reference

26 September 2017

6

1 reference

26 September 2017

982-1018

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199651060-00009

26 September 2017

0 references

cites work

Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

1 reference

12 December 2020

Efficacy and cost-effectiveness of simvastatin and gemfibrozil in the treatment of hyperlipidaemia

1 reference

12 December 2020

Predictive value for coronary heart disease of baseline high-density and low-density lipoprotein cholesterol among Fredrickson type IIa subjects in the Helsinki Heart Study

1 reference

12 December 2020

Gemfibrozil-induced myopathy

1 reference

12 December 2020

Management of primary hyperlipidemia

1 reference

12 December 2020

Gemfibrozil treatment of the high triglyceride-low high-density lipoprotein cholesterol trait in men with established atherosclerosis

1 reference

12 December 2020

Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study

1 reference

12 December 2020

Gemfibrozil treatment is associated with elevated adrenal androgen, androstanediol glucuronide and cortisol levels in dyslipidemic men

1 reference

12 December 2020

Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia

1 reference

12 December 2020

Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy

1 reference

12 December 2020

Long-term effect of gemfibrozil on coronary heart disease risk profile of patients with primary combined hyperlipidaemia

1 reference

12 December 2020

Fat transport in lipoproteins--an integrated approach to mechanisms and disorders

1 reference

12 December 2020

Primary hypertriglyceridemia with borderline high cholesterol and elevated apolipoprotein B concentrations. Comparison of gemfibrozil vs lovastatin therapy

1 reference

12 December 2020

Cholesterol-lowering agent myopathy (CLAM)

1 reference

12 December 2020

Reduction in Q wave myocardial infarctions with gemfibrozil in the Helsinki Heart Study

1 reference

12 December 2020

[Multicenter clinical, double blind, and randomized study to assess the effectiveness and safety of binifibrate versus gemfibrozil in type IIa, IIb, and IV hyperlipidemia]

1 reference

12 December 2020

Safety of combined pravastatin-gemfibrozil therapy

1 reference

12 December 2020

Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia

1 reference

12 December 2020

Effects of simvastatin versus gemfibrozil on lipids and glucose control in patients with non-insulin-dependent diabetes mellitus. NIDDM Study Group.

1 reference

12 December 2020

Regression of atherosclerosis. Benefit can be expected from low LDL-C and high HDL-C levels

1 reference

12 December 2020

Risk factors for myocardial infarction in the Stockholm prospective study. A 14-year follow-up focussing on the role of plasma triglycerides and cholesterol

1 reference

12 December 2020

Effect of gemfibrozil on the regulation of HDL subfractions in hypertriglyceridaemic patients

1 reference

12 December 2020

Once-daily, extended-release gemfibrozil in patients with dyslipidemia. The Lopid SR Work Group I

1 reference

12 December 2020

Cost implications of lipid-lowering treatments

1 reference

12 December 2020

Different effects of fibrates on the lipoprotein profile. Comparison of the effectiveness of gemfibrozil and bezafibrate in various types of hyperlipoproteinemia

1 reference

12 December 2020

Acute compartment syndrome: an unusual presentation of gemfibrozil induced myositis.

1 reference

12 December 2020

Apparent reduced absorption of gemfibrozil when given with colestipol

1 reference

12 December 2020

Prevention of atherosclerosis in diabetes: emphasis on treatment for the abnormal lipoprotein metabolism of diabetes

1 reference

12 December 2020

Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia

1 reference

12 December 2020

Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia

1 reference

12 December 2020

Reactivity of gemfibrozil 1-o-beta-acyl glucuronide. Pharmacokinetics of covalently bound gemfibrozil-protein adducts in rats

1 reference

12 December 2020

Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia

1 reference

12 December 2020

Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men

1 reference

12 December 2020

The Helsinki Heart Study: coronary heart disease incidence during an extended follow-up

1 reference

12 December 2020

Reducing hypertriglyceridemia in elderly patients with cerebrovascular disease stabilizes or improves cognition and cerebral perfusion

1 reference

12 December 2020

Gemfibrozil-induced impotence

1 reference

12 December 2020

Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study

1 reference

12 December 2020

A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia

1 reference

12 December 2020

Effects of gemfibrozil on low-density lipoprotein particle size, density distribution, and composition in patients with type II diabetes.

1 reference

12 December 2020

Treatment of hyperlipidemia in renal transplant patients with gemfibrozil and dietary modification

1 reference

12 December 2020

Inhibition of endothelial cell expression of plasminogen activator inhibitor type-1 by gemfibrozil

1 reference

12 December 2020

Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia

1 reference

12 December 2020

Understanding and treating dyslipidemia associated with noninsulin-dependent diabetes mellitus and hypertension.

1 reference

12 December 2020

Diet and exercise and gemfibrozil therapy for the management of dyslipidemia: a CEN study. Clinical Experience Network

1 reference

12 December 2020

The effects of bile salts and lipids on the physicochemical behavior of gemfibrozil

1 reference

12 December 2020

Comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia: the Finnish Multicenter Study

1 reference

12 December 2020

Effects of gemfibrozil on the oxygen transport properties of erythrocytes.

1 reference

12 December 2020

Improvement in symptoms of depression and in an index of life stressors accompany treatment of severe hypertriglyceridemia.

1 reference

12 December 2020

A multicenter double-blind study comparing lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia

1 reference

12 December 2020

Gemfibrozil interaction with warfarin sodium (coumadin)

1 reference

12 December 2020

1 reference

12 December 2020

Antihyperlipidaemic agents. Drug interactions of clinical significance

1 reference

12 December 2020

Direct effects of gemfibrozil on the fibrinolytic system. Diminution of synthesis of plasminogen activator inhibitor type 1

1 reference

12 December 2020

Gemfibrozil improves abnormalities of lipid metabolism in patients on continuous ambulatory peritoneal dialysis: the role of postheparin lipases in the metabolism of high-density lipoprotein subfractions

1 reference

12 December 2020

Gemfibrozil Also Corrects Dyslipidemia in Postmenopausal Women and Smokers

1 reference

12 December 2020

Comparison of gemfibrozil and lovastatin in patients with high low-density lipoprotein and low high-density lipoprotein cholesterol levels

1 reference

12 December 2020

Effect of gemfibrozil in men with primary isolated low high-density lipoprotein cholesterol: a randomized, double-blind, placebo-controlled, crossover study.

1 reference

12 December 2020

Low density lipoprotein density and composition in hypercholesterolaemic men treated with HMG CoA reductase inhibitors and gemfibrozil

1 reference

12 December 2020

Gemfibrozil in hyperlipidaemic patients with peripheral arterial disease: some undiscovered actions

1 reference

12 December 2020

Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study

1 reference

12 December 2020

Comparison of lovastatin and gemfibrozil in normolipidemic patients with hypoalphalipoproteinemia

1 reference

12 December 2020

Identification of individuals at high risk for myocardial infarction

1 reference

12 December 2020

Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety

1 reference

12 December 2020

Comparative effects of gemfibrozil and clofibrate in type III hyperlipoproteinemia

1 reference

12 December 2020

Hyperlipidemia after renal transplantation: treatment with gemfibrozil

1 reference

12 December 2020

The cost of screening for hypercholesterolaemia– results from a clinical trial in Swedish primary health care

1 reference

12 December 2020

Altering Triglyceride Concentrations Changes Insulin-Glucose Relationships in Hypertriglyceridemic Patients: Double-Blind Study With Gemfibrozil With Implications for Atherosclerosis

1 reference

12 December 2020

The influence of simvastatin alone or in combination with gemfibrozil on plasma lipids and lipoproteins in patients with type III hyperlipoproteinemia

1 reference

12 December 2020

Medication compliance and serum lipid changes in the Helsinki Heart Study

1 reference

12 December 2020

Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemia

1 reference

12 December 2020

A comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia.

1 reference

12 December 2020

Effects of lovastatin and gemfibrozil on high-density lipoprotein subfraction density and composition in patients with familial hypercholesterolemia

1 reference

12 December 2020

Treatment of combined hyperlipidemia with lovastatin versus gemfibrozil: a comparison study

1 reference

12 December 2020

Insoluble complex formation between LDL and arterial proteoglycans in relation to serum lipid levels and effects of lipid lowering drugs

1 reference

12 December 2020

Effect of gemfibrozil administration on biliary lipid secretion in hyperlipidemic patients. A crossover study with clofibrate

1 reference

12 December 2020

Lipid abnormalities in chronic uremic patients. Response to treatment with gemfibrozil.

1 reference

12 December 2020

Lipoproteins and coronary heart disease in the Helsinki Heart Study

1 reference

12 December 2020

Effects of gemfibrozil on serum apolipoprotein E distribution in hypercholesterolemic patients

1 reference

12 December 2020

Pravastatin vs gemfibrozil in the treatment of primary hypercholesterolemia. The Italian Multicenter Pravastatin Study I

1 reference

12 December 2020

Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia

1 reference

12 December 2020

Gemfibrozil: interaction with glyburide

1 reference

12 December 2020

Mechanism of the gemfibrozil-induced decrease in the transfer of cholesterol esters from high density lipoproteins to very low and low density lipoproteins

1 reference

12 December 2020

Costs and benefits of risk factor reduction for coronary heart disease: insights from screening and treatment of serum cholesterol

1 reference

12 December 2020

The Helsinki Heart Study: an 8.5-year safety and mortality follow-up

1 reference

12 December 2020

Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability

1 reference

12 December 2020

Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage

1 reference

12 December 2020

Hypertriglyceridemia in diabetes. An approach to management

1 reference

12 December 2020

Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease

1 reference

12 December 2020

The triglyceride issue revisited. Findings from the Helsinki Heart Study.

1 reference

12 December 2020

Rheumatic manifestations of hyperlipidemia and antihyperlipidemia drug therapy

1 reference

12 December 2020

HDL cholesterol predicts coronary heart disease mortality in older persons

1 reference

12 December 2020

Effects of gemfibrozil and ketoconazole on human apolipoprotein AI, B and E levels in two hepatoma cell lines, HepG2 and Hep3B

1 reference

12 December 2020

Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia

1 reference

12 December 2020

Lovastatin/gemfibrozil myopathy: a clinical, histochemical, and ultrastructural study

1 reference

12 December 2020

The effects of fibrates on lipoprotein and hemostatic coronary risk factors

1 reference

12 December 2020

Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin

1 reference

12 December 2020

Creatinine rise after fibrate therapy in renal graft recipients

1 reference

12 December 2020

Management of hyperlipidaemia

1 reference

12 December 2020

Decreasing triglyceride by gemfibrozil therapy does not affect the glucoregulatory or antilipolytic effect of insulin in nondiabetic subjects with mild hypertriglyceridemia

1 reference

12 December 2020

Effect of gemfibrozil on the concentration and composition of very low density and low density lipoprotein subfractions in hypertriglyceridemic patients

1 reference

12 December 2020

Sexual dysfunction after gemfibrozil

1 reference

12 December 2020

Cholesterol absorption and synthesis during pravastatin, gemfibrozil and their combination

1 reference

12 December 2020

Effect of gemfibrozil and lovastatin on postprandial lipoprotein clearance in the hypoalphalipoproteinemia and hypertriglyceridemia syndrome.

1 reference

12 December 2020

Efficacy of Gemfibrozil in Dyslipidaemic Subjects with Suspected Heart Disease. An Ancillary Study in the Helsinki Heart Study Frame Population

1 reference

12 December 2020

Lovastatin. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia

1 reference

12 December 2020

Gemfibrozil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia

1 reference

12 December 2020

Comparison of the effects of lovastatin and gemfibrozil on lipids and glucose control in non-insulin-dependent diabetes mellitus.

1 reference

12 December 2020

Gemfibrozil in familial combined hyperlipidaemia: effect of added low-dose cholestyramine on plasma and biliary lipids

1 reference

12 December 2020

Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management

1 reference

12 December 2020

Effect of gemfibrozil on early carotid atherosclerosis in diabetic patients with hyperlipidaemia.

1 reference

12 December 2020

Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia

1 reference

12 December 2020

Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study.

1 reference

12 December 2020

Relation between baseline lipid and lipoprotein values and the incidence of coronary heart disease in the Helsinki Heart Study

1 reference

12 December 2020

A retrospective review of the use of lipid-lowering agents in combination, specifically, gemfibrozil and lovastatin

1 reference

12 December 2020

A review of drug-induced Leydig cell hyperplasia and neoplasia in the rat and some comparisons with man

1 reference

12 December 2020

Gemfibrozil enhances platelet activity in patients with combined hyperlipoproteinemia.

1 reference

12 December 2020

Effect of gemfibrozil on the concentration and composition of serum lipoproteins. A controlled study with special reference to initial triglyceride levels

1 reference

12 December 2020

Lowering of triglycerides by gemfibrozil affects neither the glucoregulatory nor antilipolytic effect of insulin in type 2 (non-insulin-dependent) diabetic patients.

1 reference

12 December 2020

Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy

1 reference

12 December 2020

Changes of lipoprotein profile in familial dysbetalipoproteinemia with gemfibrozil

1 reference

12 December 2020

Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants

1 reference

12 December 2020

Comparative study of a microporous cholestyramine analogue (filicol) and gemfibrozil for treatment of severe primary hypercholesterolemia. Short- and long-term results

1 reference

12 December 2020

Insulin action and glucose metabolism are improved by gemfibrozil treatment in hypertriglyceridemic patients.

1 reference

12 December 2020

Efficacy and tolerability of etofibrate and gemfibrozil in combined hyperlipidaemia

1 reference

12 December 2020

Post-transplant hyperlipidemia: risk factors and response to dietary modification and gemfibrozil therapy

1 reference

12 December 2020

Change in composition of high density lipoprotein during gemfibrozil therapy

1 reference

12 December 2020

Effect of gemfibrozil treatment in hypercholesterolemia on low density lipoprotein (LDL) subclass distribution and LDL-cell interaction

1 reference

12 December 2020

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

12 December 2020

Effect of gemfibrozil treatment in sulfonylurea-treated patients with noninsulin-dependent diabetes mellitus.

1 reference

12 December 2020

Serum lipoproteins, apolipoproteins and very low density lipoprotein subfractions during 6-month fibrate treatment in primary hypertriglyceridaemia

1 reference

12 December 2020

Effect of gemfibrozil on high density lipoprotein subspecies in non-insulin dependent diabetes mellitus. Relations to lipolytic enzymes and to the cholesteryl ester transfer protein activity

1 reference

12 December 2020

Effects of treatment of hypertriglyceridaemia with gemfibrozil on serum lipoproteins and the transfer of cholesteryl ester from high density lipoproteins to low density lipoproteins

1 reference

12 December 2020

Hyperlipoproteinemia in adults with renal disease

1 reference

12 December 2020

Pharmacokinetics of the combination of fluvastatin and gemfibrozil

1 reference

12 December 2020

Effects of gemfibrozil on lipids and haemostasis after myocardial infarction

1 reference

12 December 2020

Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy

1 reference

12 December 2020

Effect of gemfibrozil versus lovastatin on increased serum lipoprotein(a) levels of patients with hypercholesterolemia.

1 reference

12 December 2020

Gemfibrozil reduces plasma prothrombin fragment F1 + 2 concentration, a marker of coagulability, in patients with coronary heart disease

1 reference

12 December 2020

Influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia

1 reference

12 December 2020

Gemfibrozil absorption and elimination in kidney and liver disease

1 reference

12 December 2020

Effects of gemfibrozil on triglyceride levels in patients with NIDDM. Hyperlipidemia in Diabetes Investigators

1 reference

12 December 2020

Influences of lipid-modifying agents on hemostasis

1 reference

12 December 2020

HDL-cholesterol as a risk factor in coronary heart disease. An update of the Helsinki Heart Study

1 reference

12 December 2020

Effect of gemfibrozil on composition of lipoproteins and distribution of LDL subspecies

1 reference

12 December 2020

Therapy of hypercholesterolemia and hypertriglyceridemia. Comparison of hypolipemic effects of lovastatin and gemfibrozil

1 reference

12 December 2020

HDL metabolism in HDL deficiency associated with familial hypertriglyceridemia: effect of treatment with gemfibrozil

1 reference

12 December 2020

Gemfibrozil-induced impotence

1 reference

12 December 2020

Therapeutic effects of bezafibrate and gemfibrozil in hyperlipoproteinaemia type IIa and IIb.

1 reference

12 December 2020

Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias

1 reference

12 December 2020

Gemfibrozil reduces postprandial lipemia in non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

Gemfibrozil-induced impotence

1 reference

12 December 2020

The hypolipidemic effects of gemfibrozil in type V hyperlipidemia. A double-blind, crossover study

1 reference

12 December 2020

Comparison of low-dose simvastatin and gemfibrozil in the treatment of elevated plasma cholesterol. A multicenter study. The Simvastatin Study Group

1 reference

12 December 2020

Gemfibrozil cost-benefit study. Targeting subgroups for effective hyperlipidaemia drug therapy

1 reference

12 December 2020

The effect of renal function on the pharmacokinetics of gemfibrozil

1 reference

12 December 2020

Treatment of nephrotic hyperlipoproteinemia with gemfibrozil

1 reference

12 December 2020

Hypercholesterolemia treatment in a renal transplant patient.

1 reference

12 December 2020

Effects of gemfibrozil (Lopid) on hyperlipidemia in acitretin-treated patients. Results of a double-blind cross-over study

1 reference

12 December 2020

Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment

1 reference

12 December 2020

Gemfibrozil therapy in primary type II hyperlipoproteinemia: effects on lipids, lipoproteins and apolipoproteins

1 reference

12 December 2020

Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study

1 reference

12 December 2020

Treatment of hyperlipidemia in heart transplant recipients with gemfibrozil +/- lovastatin

1 reference

12 December 2020

Effects of gemfibrozil on plasma lipoprotein-apolipoprotein distribution and platelet reactivity in patients with hypertriglyceridemia.

1 reference

12 December 2020

Dyslipidaemia in non-insulin dependent diabetes: the need for a clinical intervention trial

1 reference

12 December 2020

The triglyceride issue: a view from Framingham

1 reference

12 December 2020

Inhibition of HMG-CoA reductase in mononuclear cells during gemfibrozil treatment

1 reference

12 December 2020

10.2165/00003495-199651060-00009

Identifiers

DOI

1 reference

PubMed ID

8736620

Dimensions Publication ID

26 September 2017

0 references

1 reference

PubMed ID

8736620